New horizons in allergy diagnostics and treatment

New horizons in allergy diagnostics and treatment

Tools

PrintSend e-mail

Pdf version

Rafał

Pawliczak

Pol Arch Med Wewn

2013

pii: AOP_13_020

PMID: 

23611954

Published online: 

April 24, 2013

tabs-grup

• Abstract(active tab)

According to several studies both doctors and patients impatiently awaiting new treatments for allergic diseases. After anti-leukotrienes and omalizumab introduction to asthma treatment, no new class of drugs was registered for use. Drug development in allergy covers several pathways. Most of them are promising. In this review some aspects of new drugs development were discussed. New class of drugs such as cytokine antagonists, kinase inhibitors, transcription factors antagonists are close to come. Moreover, new anti IgE antibodies and PDE4 inhibitors are also under development. Some useful diagnostic tool have been already introduced. Unfortunately, no preventive options allowing for sensitization prophylaxis are available.

Key words 

asthma, allergy, new treatment
s

• NIHPA Author Manuscripts >
• PMC3630076

Am J Clin Exp Immunol. Author manuscript; available in PMC 2013 April 18.

Published in final edited form as:

Am J Clin Exp Immunol. 2012 June 30; 1(1): 20–27.

Published online 2012 April 23.

PMCID: PMC3630076

NIHMSID: NIHMS459240

Interleukin 13 and the evolution of asthma therapy

Gabriele Grünig,¹ David B. Corry,² Joan Reibman,³ and Marsha Wills-Karp⁴

Author information ► Copyright and License information ►

Summary

This is a concise review on Interleukin (IL)-13 and the evolution of asthma therapy, from discovery of the molecule, the identification of its pathogenic role in animal models of asthma, to the development of clinically successful neutralizing agents. The translational path from basic research to clinical application was not sequential as expected but random with respect to the tools (molecular & cell biology, animal models, human studies) used and to the application of academic versus industry research. The experiences with the development of neutralizing anti-IL-13 reagents emphasize the need for inclusion of a biomarker assay in the clinical trials that both identifies individuals that actually have aberrant expression of the pathway of interest and allows determining whether the target of interest is neutralized.

Formats:

• Abstract
 | 
• Article
 | 
• PubReader
 | 
• ePub (beta)
 | 
• PDF (797K)

Original research

Association between autoimmune reactions and severity of atopic dermatitis in children with herpes virus infection

Pavel Samoylikov, Valentina Gervazieva and Sergey Kozhevnikov

For all author emails, please log on.

World Allergy Organization Journal 2013, 6:8 doi:10.1186/1939-4551-6-8

Published: 29 April 2013

Abstract (provisional)

Background

Patients with atopic dermatitis (AD) can develop autoantibodies against intracellular proteins. AD patients often suffer from herpes viruses (HV) infection which complicates the inflammatory process in the skin. The aim of the study was to reveal IgE and IgG antibodies (abs) specific to some skin antigens and to compare their levels with the severity of AD with HV infection in children.

Methods

IgE and IgG abs specific to tissue antigens, total IgE, IgE-abs to environmental common allergens as well as IgG abs specific to HV were detected in serum samples by ELISA in 157 AD children.

Results

IgE and IgG antibody production to keratin and elastin was observed in children with AD and elevated proportionally to the severity of AD. IgG -- abs to herpes simplex virus was increased in children and associated with the severity of clinical course of AD.

Conclusion

Our data shown that clinical course of severe AD is accompanied with autoimmune response to epidermal antigens (keratin and elastin). Elevated levels of the autoantibodies, especially against the background of HV infection may be useful serological parameter for monitoring of the disease activity.

The complete article is available as a provisional PDF. The fully formatted PDF and HTML versions are in production.

Allergen-Specific Immunotherapy for the Treatment of Allergic Rhinoconjunctivitis and/or Asthma: Comparative Effectiveness Review

Executive Summary – Mar. 27, 2013

Allergen-Specific Immunotherapy for the Treatment of Allergic Rhinoconjunctivitis and/or Asthma: Comparative Effectiveness Review

Formats

• View PDF(PDF) 878 kB  
• 
  

Table of Contents

• Background
• Scope and Key Questions
• Analytic Framework
• Methods
• Results
• Discussion
• Future Research
• Conclusions
• Tables
• References
• Abbreviations

Review

You have free access to this content

Human dendritic cell subsets

1. Matthew Collin^*, 
2. Naomi McGovern,
3. Muzlifah Haniffa

DOI: 10.1111/imm.12117

This article is protected by copyright. All rights reserved.

Issue

Immunology

Accepted Article (Accepted, unedited articles published online and citable. The final edited and typeset version of record will appear in future.)

Additional Information(Show All)

Author InformationPublication History

1. This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as an ‘Accepted Article’, doi: 10.1111/imm.12117

Get PDF (724K)

The orchestration of effective immunity in vertebrates depends upon dendritic cells (DCs), a class of bone marrow-derived cells found in the blood, epithelia and lymphoid tissues. DCs are equipped with molecular sensors and antigen processing machinery to recognise pathogens, integrate chemical information and to guide the specificity, magnitude and polarity of immune responses. Recent advances have helped to define DCs as a distinct haematopoietic lineage and to establish functional specialization between different DC subsets. The aim of this review is to present a coherent framework for understanding human DC subsets and their functional roles in vivo.

Get PDF (724K)

Airway remodelling in asthma and novel therapy

 

Vol. 31, No. 1, March 2013 > Manuyakorn

Airway remodelling in asthma and novel therapy

Wiparat Manuyakorn, Peter H Howarth, Stephen T Holgate

Abstract

Asthma is an airway inflammatory disease with functional and structural changes, leading to bronchial hyperresponsiveness (BHR) and airflow obstruction. Airway structural changes or airway remodelling consist of epithelial injury, goblet cell hyperplasia, subepithelial layer thickening, airway smooth muscle hyperplasia and angiogenesis. These changes were previously considered as a consequence of chronic airway inflammation. However, several studies have demonstrated that inflammation and remodelling can occur as separate but parallel aspects of the asthmatic process. As such there is increasing evidence for the role of mechanocompressive forces within the asthmatic airway contributing to airway structural changes. Furthermore, it is unclear what is the best treatment to modify remodelling and which component to target. There is also a need to identify asthma phenotype that might specifically respond to novel therapies such as anti-IL5, anti-IL13 and tyrosine kinase inhibitors.

Full Text: PDF 

Orally inhaled fluticasone propionate improved chronic rhinosinusitis with co-morbid asthma: report of a case

 

Vol. 31, No. 1, March 2013 > Nonaka

Orally inhaled fluticasone propionate improved chronic rhinosinusitis with co-morbid asthma: report of a case

Manabu Nonaka, Yukako Tanaka, Ruby Pawankar, Toshio Yoshihara

Abstract

Chronic rhinosinusitis and asthma are expressions of airway inflammatory diseases that frequently coexist, especially in the case of adult-onset asthma. Both conditions have similar pathological features, while one affects the upper airways and the other the lower airways. Whether the treatment of bronchial inflammation affects the severity of sinus disease remains an unanswered question. We report a case of refractory chronic rhinosinusitis with co-morbid adult-onset asthma that effectively improved upon treatment with a daily dose of 200 μg (100 μg b.i.d.) of inhaled fluticasone propionate (FP). 

Full Text: PDF 

2nd WAO International Scientific Conference (WISC 2012, Hyderabad, India 6-9 December 2012) - Abstracts

WAO Journal publishes selected collections of research articles, conference proceedings, reviews and reports as supplements, which are free to access online. All articles published in supplements are subject to peer review; meeting abstracts undergo review and selection by the conference. Find out more about publishing a supplement with BioMed Central.

Volume 6 Supplement 1

2nd WAO International Scientific Conference (WISC 2012), Abstracts

Meeting abstracts

2nd WAO International Scientific Conference (WISC 2012)

Hyderabad, India

6-9 December 2012

Edited by Ruby Pawankar, Lanny J Rosenwasser and Stephen T Holgate

Publication of this supplement was supported by the World Allergy Organization with additional support from Johnson & Johnson.

Conference website